Trial Profile
A Phase I/II Study of Eltrombopag in Patients With Chronic Myelomonocytic Leukemia and Thrombocytopenia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Chronic myelomonocytic leukaemia; Thrombocytopenia
- Focus Therapeutic Use
- 19 Apr 2021 Status changed from active, no longer recruiting to completed.
- 08 Dec 2020 Primary endpoint (Platelet response (HI-P) at 12 weeks, according to IWG 2006 criteria) has not been met, according to final results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
- 08 Dec 2020 According to final results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology, comparison with a larger historical cohort not exposed to eltrombopag (ELT) is ongoing.